Departmental Focus
The overall mission of the Oncology Department is to improve cure rates for children with cancer while reducing the side effects of therapy through a coordinated program of clinical and laboratory-based research, patient care and education. Recent gains have been seen in the treatment outcome for two of the most frequent forms of childhood cancer (a 94 percent survival rate for acute lymphoblastic leukemia and 71 percent for acute myeloid leukemia).
Oncology faculty share their unique clinical expertise with colleagues worldwide through St. Jude Global. They are also involved in all programs of the Cancer Center through research aiming at identifying novel drugs and treatment modalities, defining the clinical significance of recently discovered genetic abnormalities of cancer cells, and understanding mechanisms of cancer development and drug resistance. The ultimate goals of this research are to provide curative therapy to every child with cancer and help develop preventive measures.
Contact Us
Department of Oncology
MS 260, Room C6056
St. Jude Children's Research Hospital
262 Danny Thomas Place
Memphis, TN 38105-3678
Email: ching-hon.pui@stjude.org
Telephone: (901) 595-4329
Fax: (901) 521-1751
Preferred contact method: email
-
Greg Armstrong, MD, MSCE
Armstrong
Pediatric neuro-oncology and cancer survivorship
-
Allison Ast, MD
Ast
Integrative therapies in pediatric hematology-oncology patients
-
Aditi Bagchi, MD, PhD
Bagchi
Novel treatment approaches to treat brain tumors in infants and young children
-
Kelsey C. Bertrand, MSc, MBBS, FAAP
Bertrand
Understanding ependymoma and high-grade glioma
-
Nickhill Bhakta, MD, MPH
Bhakta
Global pediatric medicine
-
Michael W. Bishop, MD
Bishop
Osteosarcoma, bone and soft tissue sarcomas
-
Patrick K. Campbell, MD, PhD
Campbell
Langerhans cell histiocytosis and other histiocytic disorders, chronic myeloid leukemia, and quality improvement and patient safety
-
Steven Carey, MD, PhD
Carey
Management of central nervous system malignancies
-
Griffin S. Collins, MD
Collins
-
Brittany Cowfer, MD
Cowfer
Pediatric palliative oncology; pediatric leukemia
-
Matthew J. Davis, MD
Davis
-
Stephanie Dixon, MD, MPH
Dixon
Cancer survivorship; Hodgkin & non-Hodgkin lymphomas
-
Caitlyn Duffy, MD, MPH
Duffy
Implementation science, global medicine, pediatric leukemia
-
Adam D. Durbin, MD, PhD
Durbin
Transcriptional and epigenetic control in neuroblastoma
-
Matthew J. Ehrhardt, MD, MS
Ehrhardt
Hodgkin and non-Hodgkin lymphomas, cancer survivorship
-
Sara M. Federico, MD
Federico
Drug development, Ewing sarcoma, neuroblastoma
-
Developmental therapeutics in pediatric oncology
-
Paola Friedrich, MD, MPH
Friedrich
Global pediatric oncology; clinical effectiveness; health disparities; pediatric solid tumors
-
Wayne L. Furman, MD
Furman
Emeritus
-
Amar Gajjar, MD
Gajjar
Novel treatments for children with brain tumors
-
Rebecca Gardner, MD
Gardner
-
Jessica Gartrell, MD
Gartrell
Early-phase clinical trial development, sarcomas, liver tumors
-
Dylan Graetz, MD, MPH
Graetz
Global pediatric oncology; communication; pediatric solid tumors
-
Daniel M. Green, MD
Green
Adverse effects of therapy
-
Lillian Macrae Guenther, MD
Guenther
Pediatric bone sarcomas
-
Emily Hanzlik, MD
Hanzlik
Intersection between neuro-oncology and neurology
-
Saman K. Hashmi, MD
Hashmi
Medical education, quality improvement, global capacity building
-
Mark E. Hatley, MD, PhD
Hatley
Cellular and molecular origins of rhabdomyosarcoma
-
Sara Helmig, MD
Helmig
Sarcomas, quality improvement
-
Targeted leukemia therapy and clinical trials
-
Melissa M. Hudson, MD
Hudson
Health outcomes after childhood cancer
-
Hiroto Inaba, MD, PhD
Inaba
Acute lymphoblastic leukemia/lymphoma; acute myeloid leukemia
-
Sima Jeha, MD
Jeha
Childhood leukemias, developmental therapeutics
-
Lauren Jerkins, MD
Jerkins
Cellular therapy; quality improvement and patient safety
-
Liza-Marie Johnson, MD, MPH, MSB
Johnson
Ethical issues in pediatrics
-
Seth Karol, MD
Karol
Prevention of toxicity during acute leukemia therapy
-
Sue C. Kaste, DO
Kaste
Skeletal toxicities in childhood cancer survivors
-
Erica C. Kaye, MD
Kaye
Communication; early integration of palliative care in oncology
-
International outreach, rare tumors, treatment adherence
-
Deena R. Levine, MD
Levine
Pediatric palliative and end of life care
-
Michael McNeil, MD, MPH
McNeil
-
Daniel Moreira, MD, MEd
Moreira
Global pediatric oncology; evidence-based education; pediatric CNS tumors
-
Daniel A. Mulrooney, MD, MS
Mulrooney
Oncology; cancer survivorship
-
Min Ni, PhD
Ni
Metabolism in development and cancer
-
Kim E. Nichols, MD
Nichols
Heritable cancers and primary immunodeficiency syndromes
-
Esther A. Obeng, MD, PhD
Obeng
Myeloid malignancies and bone marrow failure syndromes
-
Alberto Pappo, MD
Pappo
New therapies for sarcomas and rare pediatric cancers
-
Julie Park, MD
Park
Early-phase clinical trials for recurrent childhood malignancies
-
Anand Patel, MD, PhD
Patel
Tumor recurrence in pediatric rhabdomyosarcoma
-
Melissa Perrino, MD
Perrino
Germline predisposition and genetic drivers of cancer
-
Biology and treatment of childhood leukemias
-
Ibrahim Qaddoumi, MD, MS
Qaddoumi
Low grade gliomas, global health, telemedicine and retinoblastoma
-
Matthew Rees, MD
Rees
Improvement science in pediatric oncology
-
Raul C. Ribeiro, MD
Ribeiro
Hematological malignancies
-
Charles W. M. Roberts, MD, PhD
Roberts
SWI/SNF (BAF) chromatin remodeling/tumor suppressor
-
Giles W. Robinson, MD
Robinson
Origin and genomics of medulloblastoma, translational studies
-
Carlos Rodriguez-Galindo, MD
Rodriguez-Galindo
Global medicine; pediatric solid tumors
-
Jeffrey E. Rubnitz, MD, PhD
Rubnitz
Treatment of acute myeloid leukemia
-
Jeremy Slone, MD, MPH
Slone
Global pediatric cancer epidemiology
-
Elizabeth A. Stewart, MD
Stewart
High risk pediatric solid tumors
-
Linda Stout, MD
Stout
Pediatric oncology
-
Dana Tlais, MD
Tlais
Molecular characterization of high-grade glioma
-
Anna Vinitsky, MD, MS
Vinitsky
Pediatric neuro-oncology and process improvement
-
Ruth Wang’ondu, MD, PhD
Wang’ondu
-
Jun J. Yang, PhD
Yang
Pharmacogenomics of anticancer agents and drug resistance
-
Liqin Zhu, PhD
Zhu
Stem cells in normal and malignant development